Podcast: What to expect in haematology in 2021

From off-the-shelf CAR T-cell therapy products, a big focus on drug-antibody conjugates and novel molecular compound trials to the search for new immunotherapy regimens we talk to HSANZ president Dr Leanne Berkahn about what 2021 will bring to the field...

From off-the-shelf CAR T-cell therapy products, a big focus on drug-antibody conjugates and novel molecular compound trials to the search...

Coagulation

MPN patients show higher mortality with COVID-19 ‘ruxolitinib discontinuation syndrome’

Patients with myeloproliferative neoplasms (MPN) face a higher mortality risk from COVID-19 infections than the general population, according to a new study. The findings, published in Nature, also show that patients who discontinued ruxolitinib therapy had a 'striking' increase in...

Patients with myeloproliferative neoplasms (MPN) face a higher mortality risk from COVID-19 infections than the general population, according to a...

Anaemia

One-off iron infusion works for most IDA

A single 1 g dose of intravenous iron is sufficient treatment for most patients with iron deficiency anaemia, a New Zealand study has shown. The review of 194 adult outpatients who received either 1 g of ferric carboxymaltose or iron...

A single 1 g dose of intravenous iron is sufficient treatment for most patients with iron deficiency anaemia, a New...

Blood cancers

ASH 2020 – Highlights through an Australian lens

Join the limbic and a panel of experts as they present their highlights from the virtual ASH 2020 Annual Meeting and discuss how the latest research outcomes may impact care in Australia. ...

Join the limbic and a panel of experts as they present their highlights from the virtual ASH 2020 Annual Meeting...